 Genetic Technologies Limited ASX: GTG; Nasdaq: GENE, Company, a diversified molecular diagnostics company, announced today an update to shareholders on recent achievements and upcoming milestones. As a result of the successful 4.5 million capital raise from existing shareholders, together with participation from domestic institutional and family office investors, the Company is now in compliance with Nasdaq listing requirements. The funds raised also position the Company to commence sales of its latest breast cancer and colorectal cancer risk assessment tests in both the U.S. and Australia. 